Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
6.82
+0.06 (0.89%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Serina Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Revenue
3.173.150.593.46
Revenue Growth (YoY)
2368.87%433.14%-82.93%-
Cost of Revenue
4.212.391.573.8
Gross Profit
-1.040.77-0.98-0.33
Selling, General & Admin
6.373.891.291.3
Operating Expenses
6.373.891.291.3
Operating Income
-7.41-3.13-2.27-1.63
Interest Expense
-0.71-0.56-0.02-0
Interest & Investment Income
0.280.2800.01
Other Non Operating Income (Expenses)
4.321.08-0.120.21
EBT Excluding Unusual Items
-3.51-2.33-2.41-1.42
Gain (Loss) on Sale of Investments
---0.01-0.01
Gain (Loss) on Sale of Assets
----0.03
Other Unusual Items
-3.537.6-0.270.19
Pretax Income
-7.035.27-2.68-1.26
Net Income
-7.015.27-2.68-1.26
Net Income to Common
-7.015.27-2.68-1.26
Shares Outstanding (Basic)
4222
Shares Outstanding (Diluted)
4422
Shares Change (YoY)
-15.81%86.72%0.01%-
EPS (Basic)
-1.742.30-1.25-0.59
EPS (Diluted)
-1.741.46-1.25-0.59
Free Cash Flow
-10.69-2.98-2.09-2.34
Free Cash Flow Per Share
-2.65-0.74-0.97-1.09
Gross Margin
-32.68%24.30%-165.95%-9.64%
Operating Margin
-233.50%-99.18%-383.83%-47.09%
Profit Margin
-220.87%167.11%-453.44%-36.50%
Free Cash Flow Margin
-337.05%-94.53%-352.55%-67.41%
EBITDA
-7.27-3.04-2.21-1.6
EBITDA Margin
-229.06%-96.37%--46.13%
D&A For EBITDA
0.140.090.060.03
EBIT
-7.41-3.13-2.27-1.63
EBIT Margin
-233.50%-99.18%--47.09%
Revenue as Reported
3.173.150.593.46
Source: S&P Capital IQ. Standard template. Financial Sources.